ArticleCancer management and research2026
A Prognostic Nomogram Combining Radiologic Emphysema and Clinical Parameters in Small Cell Lung Cancer.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Small cell lung cancer (SCLC) is an aggressive malignancy with poor survival. Existing prognostic models provide limited patient-level risk stratification and often overlook accessible clinical and imaging data. There remains a need for refined tools to support individualized prognostication in SCLC. Patients and Methods: We retrospectively analyzed 149 SCLC patients diagnosed between 2010 and 2014, representing a pre-immunotherapy era cohort. Demographics, CT scans, and treatment details were reviewed. Emphysema burden was quantified using an AI-based automated tool that segmented the lungs and calculated the percentage of low-attenuation areas (< -950 Hounsfield Units). Multivariate Cox regression identified predictors for overall survival (OS), informing nomogram construction. Performance was measured by Harrell's C-index and calibration plots. Validation included bootstrap resampling and a 3:1 data split. Decision curve analysis (DCA) evaluated clinical utility. Results: Age, emphysema, and treatment modality were independently associated with OS. The nomogram demonstrated excellent discrimination (C-index = 0.807; 95% confidence interval [CI], 0.771-0.843) and good calibration for 1- and 3-year survival. Internal validity was high, with a bootstrap-adjusted C-index of 0.805 (95% CI, 0.779-0.845), and performance remained robust in the validation subset (C-index = 0.740; 95% CI, 0.668-0.812). Stratification by nomogram-derived risk quartiles significantly differentiated survival (log-rank p < 0.001). DCA demonstrated superior net clinical benefit compared to treat-all or treat-none strategies across clinically relevant thresholds. Conclusion: This validated nomogram, based on three readily available variables, provides accurate survival predictions for patients with SCLC. It may assist clinicians in refining treatment strategies and enhancing shared decision-making. External validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.